482 PATENT ABSTRACTS

or polypeptide analog thus separated to ion ex- change chromatography to purify the hormone or analog and thereby recover purified hormone or polypeptide analog.

5001054

M E T H O D F O R M O N I T O R I N G G L U C O S E

Daniel Wagner assigned to Becton Dickinson and Company

5001048

E L E C T R I C A L B I O S E N S O R C O N T A I N I N G A B I O L O G I C A L

R E C E P T O R I M M O B I L I Z E D A N D S T A B I L I Z E D I N A P R O T E I N F I L M

Richard Taylor, Ingrid G Marenchie, Edward J Cook assigned to Aurthur D Little Inc

An electrical biosensor tbr analyte determina- tion is prepared by polymerization of a mixture of a biological receptor capable of binding an analyte in a sample, a protein and a polymerizing agent such as glutaraldehyde to form a poly- meric film on a transducer. The mixture pre- ferably contains a stabilizer selected from lipids, detergents and antioxidents. The receptor may be an acetylcholine receptor and the analyte, ac- etylcholine. A preferred stabilizer is a combina- tion of phosphatidyl choline and octyphenoxypolyethoxyethanol. In carrying out a determination, analyte in a sample binds to the receptor causing a change in an electrical charac- teristic of the film which is indicative of the pre- sence of the analyte. The biosensor may contain a second polymeric film that is tYee of the recep- tor and which serves as a control.

5001052

I M M U N O A S S A Y F O R F H A P A N D A N T I B O D Y U S E F U L T H E R E W I T H

Lawrence Kahan, Frank C Larson assigned to Wi~ons in Alumni Research Foundation

Antibodies, hybridomas, and immunoassays relating to a fast homoarginine-sensitive alkaline phosphatase cancer complex in serum ( F H A P ) are disclosed. FHAP is a disease (e.g. cancer) marker. One aspect of the disclosure is the measuring of the physical association of two dif- ferent components of the F H A P as part of the assay.

A method for monitoring the glucose level in a body fluid uses an apparatus which includcs a conjugate of glucose oxidase and a fluoreseent dye coated onto an optical fiber in contact with the body fluid, a source of excitation light and a f luore~ence emission detector. Glucose is ox- idized by oxygen in the body fluid causing a decrease in oxygen concentration at the enzyme. The fluorescent dye is sensitive to oxygen quenching so that. when the oxygen concentra- tion decreases, fluorescence emission increases in direct proportion to the glucose concentration in the fluid.

5001055

P R O C E S S F O R P R O D U C I N G P H Y S I O L O G I C A L L Y A C T I V E

S U B S T A N C E

Kazutom Imahori, Isao Tomioka, Hirosh Nakajima, Senj Kitabatake, Tokyo, Japan as- signed to Unitika Ltd

A process for producing a physiologically active substance by a combined enzymatic method is disclosed. In the combined enzymatic method, a reactant solution containing a precursor or pre- cursors for the physiologically active substance, AXP, and a divalent metal ion is supplied at one end of a reactor incorporating either the com- bined enzymatic reaction system (a) or (b), wherein (a) is a reaction system including an en- zyme for converting AMP to ADP. an enzyme for converting ADP to ATP. and an enzyme which catalyzes the synthesis of the phys- iologically active substance as it converts ATP to AMP; and (b) is a reaction system including an enzyme for converting ADP to ATP and an en- zyme which catalyzes the synthesis of the phys- iologically active substance as it converts ATP to ADP, wherein the concentration of the divalent metal ion supplied into the reactor is held at a level no higher than 30 mM while the concentra- tion of the AXP is held below that of that of the precursor or precursors for the physilogically ac- tive substance, and the physiologically active substance produced is withdrawn from the other end of the reactor.